Arcus Biosciences Investor Relations Material
Latest events
Study Update
Arcus Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arcus Biosciences Inc
Access all reports
Arcus Biosciences Inc (RCUS) is a clinical-stage biopharmaceutical company focused on the development of cancer immunotherapies. By leveraging underexploited biological opportunities, Arcus aims to create treatments that can significantly improve patient outcomes. The company's product pipeline features a range of candidates, including AB928, a dual antagonist for adenosine receptors A2aR and A2bR, in combination with an anti-PD-1 antibody (AB122) and chemotherapy for treating metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies. The company is headquartered in Hayward, California, and its shares are listed on the NYSE.
Key slides for Arcus Biosciences Inc
Study Update
Arcus Biosciences Inc
Q1 2025
Arcus Biosciences Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
RCUS
Country
🇺🇸 United States